ReviewCJC open2026
Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.
Review in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF) is often associated with obesity and metabolic dysfunction. Recent data suggest that incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide improve cardiovascular outcomes in patients with HFpEF or HFmrEF both with and without diabetes. However, whether the effects differ by diabetes status across the broader literature remains unclear. Methods: MEDLINE and Embase were searched through October 2025 to identify randomized controlled trials (RCTs), post-hoc RCT analyses, and observational studies evaluating GLP-1RAs and tirzepatide effects on cardiovascular outcomes in patients with HFpEF or HFmrEF. Meta-regression examined effect modification by type 2 diabetes (T2D) status. Exploratory network meta-analysis of RCTs was performed to evaluate comparative efficacy across therapies. Results: Eleven studies met the inclusion criteria. In a meta-regression of RCTs, all Conclusions: Incretin-based therapies with GLP-1RA activity reduce HF hospitalization and events in patients with HFpEF or HFmrEF, with comparable benefits irrespective of T2D status. These findings support cardiovascular benefits of incretin-based therapies beyond glucose lowering and reinforce their role in obesity-associated HFpEF and HFmrEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.